A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs Voclosporin (Primary) ; Corticosteroid; Methylprednisolone; Prednisone
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms AURA; AURA-LV
- Sponsors Aurinia Pharmaceuticals
- 11 Oct 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present new data highlighting the important role that LUPKYNIS in Treating Lupus Nephritis will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27.
- 05 Jun 2024 According to Aurinia Pharmaceuticals Inc. media release, data from the study will be presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15.
- 05 Jun 2024 Results presented in the Aurinia Pharmaceuticals Media Release.